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Abstract
Introduction:  Refsum disease is a potentially lethal and disabling condition associated with
retinitis pigmentosa in which early treatment can prevent some of the systemic manifestations.
Case presentation: We present the cases of two brothers with a diagnosis of retinitis
pigmentosa from childhood in whom Refsum disease was subsequently diagnosed midlife, after
routine enquiry into hand and feet abnormalities. Subsequent treatment through dietary
modification stabilised visual impairment and has prevented development of neurological
complications to date.
Conclusion: It is therefore important to consider the diagnosis of Refsum disease in any patient
with autosomal recessive or simplex retinitis pigmentosa, and to enquire about the presence of
"unusual" feet or hands in such patients.
Introduction
Refsum disease is a potentially lethal and disabling condi-
tion associated with retinitis pigmentosa in which early
treatment can prevent some of the systemic manifesta-
tions. We present the cases of two brothers with a diagno-
sis of retinitis pigmentosa from childhood in whom
Refsum disease was subsequently diagnosed midlife, after
routine enquiry into hand and feet abnormalities. Subse-
quent treatment through dietary modification stabilised
visual impairment and has prevented development of
neurological complications to date.
Case presentation
Two brothers, both Caucasian and native to South Africa,
of non-consanguineous parents were referred to the reti-
nal clinic at our hospital having recently moved to the
United Kingdom. The elder brother, aged 43, was myopic
and developed night blindness and peripheral visual field
loss at six years of age. Following clinical examination and
electrodiagnostic testing in South Africa a diagnosis of
retinitis pigmentosa (RP) was made. He underwent
uncomplicated cataract extraction with lens implantation
in the right eye at the age of 40. He then moved to the
United Kingdom and presented for review. On examina-
tion visual acuities were 6/24 OD and 6/12 OS, and due
to the severity of his visual field loss he was eligible to be
registered blind. On further questioning he mentioned
that he had always had "unusual" feet. Examination
showed abnormal 2nd and 3rd toes with a short 4th meta-
tarsal (Figure 1). Neurological assessment including clini-
cal examination and electrophysiology revealed an
unremarkable CNS examination with peripheral exami-
nation showing normal symmetrical reflexes and sensa-
tion with normal gait and no evidence of ataxia. A blood
sample was sent for biochemical analysis, showing serum
phytanic acid levels which were raised at 297 µm/L (nor-
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mal range: 0–15 µm/L) with pristinate and very long
chain fatty acids being within normal limits, thus con-
firming the diagnosis of Refsum disease (RD).
The younger brother, aged 38, had also been diagnosed
with RP in South Africa at around the same time as his
elder sibling. He complained of reduced taste and
described a ring scotoma in his mid peripheral vision. Vis-
ual acuities were 6/6 in both eyes and perimetry revealed
constricted visual fields. Examination of the ocular fundi
showed extensive perivascular bone spicule intra-retinal
pigmentation in the peripheral retinae (Figure 2). He also
had abnormal toes with a short 4th metatarsal similar to
his elder brother. Electrophysiology demonstrated evi-
dence of peripheral neuropathy and the Pennsylvanian
test for olfactory sensation was reduced. Neurological
assessment was otherwise unremarkable. Serum phytanic
acid was found to be elevated at 265 µm/L with pristinate
and very long chain fatty acids within normal limits, con-
firming the diagnosis of RD. There were no other family
members with abnormal toes or with any other significant
medical or ocular history.
Both brothers started a special RD diet and serum phy-
tanic acid levels have been reduced significantly as a con-
sequence. Although their visual impairment is
unchanged, the younger sibling reported an improvement
in his sense of taste and smell and neither sibling has
shown any sign of neurological complications to date.
Discussion
RP comprises a group of genetic conditions affecting 1 in
3000 to 4000 in the population, leading to progressive
photoreceptor degeneration and visual loss [1]. RP is also
seen as part of several syndromic conditions, some with
severe neurological features. RD, Bassen-Kornsweig syn-
drome, vitamin E deficiency, and gyrate atrophy are exam-
ples of conditions within this group that are amenable to
dietary modification that can influence the course of dis-
ease.
RD is an autosomal recessive disease with an incidence
thought to be less than 1:250000, although the exact inci-
dence and prevalence of the disorder in the general popu-
lation is not known. Dietary phytanic acid (a branched
chain fatty acid) accumulates within the body due to an
abnormality in a mitochondrial enzyme phytanic acid α-
hydroxylase [2]. The condition shows genetic heterogene-
ity with one locus on chromosome 10 [3] and a second
located on chromosome 6 [4]. Phytanic acid accumulates
The feet of the elder sibling showed abnormal second and  third toes with a shortened fourth metatarsal Figure 1
The feet of the elder sibling showed abnormal second 
and third toes with a shortened fourth metatarsal.
Extensive perivascular "bone spicule" pigmentation seen in both fundi of the younger sibling Figure 2
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in retinal pigment epithelium and other tissues and causes
cellular death through calcium deregulation, free radical
formation and apoptosis [5]. Phytanic acid is not only ele-
vated in RD, but also in other peroxisomal disorders.
However, these can be distinguished by molecular genetic
analysis and clinical phenotype.
The clinical manifestations of RD affect the eyes, nervous
system, bones and skin, and most patients are sympto-
matic before the age of twenty but may present as late as
the fifth decade [6].
Bone spicule retinopathy is a universal and usually early
sign in RD. Many patients have noticed night blindness
prior to the onset of other symptoms and have constricted
visual fields at presentation [6]. Cataract is also a frequent
finding in almost 50% of all RD patients [6].
There is a symmetrical mixed motor and sensory polyneu-
ropathy initially affecting the distal lower limbs, which is
chronic and progressive in nature and usually preceded by
visual symptoms. Many patients also exhibit cochlear
hearing loss. Impaired sense of smell presents early in the
disease and is thought to be a universal feature [7]. Cere-
bellar signs tend to develop later.
Bony abnormalities are seen in over a third of patients and
tend to be symmetrical and bilateral in nature [8]. The
short tubular bones of the hands and feet are most often
affected, in particular the terminal phalanx of the thumb
and the fourth metatarsal.
The skin can also be affected with rough scaly thickening
seen over the extremities (ichthyosis) [9]. Cardiac abnor-
malities have also been reported, including cardiomyopa-
thy and conduction disturbances, and may be responsible
for causes of sudden death in RD [10]. Reports of cardiac
arrhythmias, as well as neurological abnormalities indi-
cate that Refsum patients should therefore be managed by
a multidisciplinary team.
Treatment for RD is aimed at lowering the serum levels of
phytanic acid. Phytanic acid comes exclusively from exog-
enous sources and hence dietary restriction of products
rich in phytanic acid, such as dairy products and ruminant
meats and fat, helps to control serum levels. Restriction of
green vegetables has found to be unnecessary as chloro-
phyll bound phytol has poor bioavailability. Diets which
are low in phytanic acid are extremely unpalatable and
consequently regimens now include poultry, pork, fruit
and vegetables [11].
Plasmapheresis [12] or lipopheresis [13] can be used in
the event of acute arrhythmias or extreme weakness.
Where dietary control has been inadequate, these treat-
ments have been shown to help improve the clinical pic-
ture.
Maintenance of normal serum phytanic acid levels has
been associated with improvement in motor nerve con-
duction velocities, ataxia and stabilisation of the progres-
sion of RP [14]. Retinal changes are usually irreversible
and hence dietary regimens should be implemented as
soon as the diagnosis is made.
Conclusion
RD is a potentially lethal and disabling disease, which is
amenable to treatment. Brief neurological screening [15]
and smell testing [7] of patients with RP have been sug-
gested as possible strategies to identify those who require
formal biochemical testing in order to increase the diag-
nostic yield of RD. Enquiry into the presence of "unusual"
feet and hands, as with the cases we have described, may
also help distinguish those patients with RD from those
with RP alone. However, in view of the severity of the dis-
ease, and the fact that it is treatable, phytanic acid testing
should be carried out in all cases of autosomal recessive or
simplex RP. Early diagnosis of the condition and initia-
tion of an appropriate diet is vital, in order to prevent dis-
ease progression and the subsequent development of
severe neurological involvement.
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